Radiopharm Theranostics Limited (ASX:RAD)
Australia · Delayed Price · Currency is AUD 0.0090
0.00 (0.00%)
Sep 11, 2026, 9:59 AM AEST
Radiopharm Theranostics Balance Sheet
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Equivalents | 4.14 | 29.12 | 18.58 | 11.7 | 26.98 |
Cash & Short-Term Investments | 4.14 | 29.12 | 18.58 | 11.7 | 26.98 |
Cash Growth | -85.79% | 56.75% | 58.77% | -56.64% | 99486.97% |
Accounts Receivable | 1.23 | - | - | 0.1 | 0.06 |
Other Receivables | 16.22 | 10.4 | 0.99 | 4.36 | 0 |
Receivables | 17.45 | 10.4 | 0.99 | 4.47 | 0.06 |
Other Current Assets | 0.34 | 0.34 | 3.29 | 0.13 | 0.23 |
Total Current Assets | 21.93 | 39.85 | 22.85 | 16.3 | 27.26 |
Property, Plant & Equipment | 0.05 | 0.05 | 0.06 | 0.07 | 0 |
Other Intangible Assets | 38.16 | 46.57 | 49.09 | 58.54 | 56.08 |
Other Long-Term Assets | - | - | 0.04 | 0.04 | 0.04 |
Total Assets | 60.13 | 86.48 | 72.04 | 74.95 | 83.38 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Accounts Payable | 5.47 | 6.35 | 6.43 | 2.96 | 1.19 |
Accrued Expenses | 5.53 | 3.2 | 2.57 | 2.11 | 1.02 |
Current Unearned Revenue | 0.81 | 1.72 | - | - | - |
Other Current Liabilities | 7.09 | 3.66 | 8.57 | 8.16 | 5.66 |
Total Current Liabilities | 18.9 | 14.93 | 17.58 | 13.23 | 7.88 |
Other Long-Term Liabilities | 18.91 | 28.68 | 27.11 | 16.14 | 12.54 |
Total Liabilities | 37.81 | 43.61 | 44.68 | 29.37 | 20.42 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Common Stock | 209.93 | 176.56 | 100.68 | 97.23 | 86.76 |
Retained Earnings | -199.66 | -145.73 | -111.34 | -65.35 | -30.91 |
Comprehensive Income & Other | 14.41 | 13.97 | 38.78 | 12.51 | 7.11 |
Total Common Equity | 24.69 | 44.79 | 28.12 | 44.38 | 62.96 |
Minority Interest | -2.36 | -1.92 | -0.77 | 1.19 | - |
Shareholders' Equity | 22.32 | 42.87 | 27.35 | 45.58 | 62.96 |
Total Liabilities & Equity | 60.13 | 86.48 | 72.04 | 74.95 | 83.38 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Net Cash (Debt) | 4.14 | 29.12 | 18.58 | 11.7 | 26.98 |
Net Cash Growth | -85.79% | 56.75% | 58.77% | -56.64% | - |
Net Cash Per Share | 0.00 | 0.01 | 0.05 | 0.04 | 0.15 |
Filing Date Shares Outstanding | 3,544 | 2,365 | 2,173 | 339.31 | 255.43 |
Total Common Shares Outstanding | 3,544 | 2,365 | 460.37 | 339.31 | 255.43 |
Working Capital | 3.03 | 24.92 | 5.27 | 3.07 | 19.39 |
Book Value Per Share | 0.01 | 0.02 | 0.06 | 0.13 | 0.25 |
Tangible Book Value | -13.47 | -1.78 | -20.96 | -14.16 | 6.89 |
Tangible Book Value Per Share | -0.00 | -0.00 | -0.05 | -0.04 | 0.03 |